Study Completed

Atrial Fibrillation

Bayer Identifier:

18735

ClinicalTrials.gov Identifier:

NCT02960880

EudraCT Number:

Not Available

EU CT Number:

Not Available

Real-world comparative effectiveness of stroke prevention in patients with atrial fibrillation treated with rivaroxaban vs. vitamin k antagonists

Trial purpose

The aim of this study is to assess the real world comparative effectiveness of Rivaroxaban prescribed in non-valvular atrial fibrillation (NVAF) routine care patients in Germany.

Key Participants Requirements

Sex

Both

Age

18 - N/A

Inclusion Criteria
- First dispense date of Rivaroxaban (15mg or 20mg - PZN based) or Phenprocoumon (PZN based) between January 1, 2012 and December 31, 2015
- At least two verified outpatient diagnoses or one inpatient diagnosis (main or secondary diagnosis) of NVAF (ICD-10 GM I48.0/I48.1/I48.2/I48.9) in the individual time frame of 4 quarters before the index date (pre-index period) or within the index quarter
- Patients will be required to have 4 quarters of enrollment for the assessment of baseline characteristics and be observable and insured in the database for at least one day after their individual index date (post-index period)
- ≥ 18 years of age
Exclusion Criteria
- Patients with valvular AF [4 quarters prior to the index date]
- Pregnancy [4 quarters prior to index date]
- Malignant cancers [4 quarters prior to the index date or “condition after”]
- Transient cause of AF [4 quarters prior to index date]
- Patients with VTE (pulmonary embolism or DVT) [60 days before index]
- Patients with major surgery defined as hip or knee replacement [60 days before index]
- Prescriptions of OACs (Rivaroxaban, VKA, Dabigatran, Apixaban) before index date [4 quarters prior to index date]
- Patients receiving more than one anticoagulant substance (Apixaban, Dabigatran, Rivaroxaban or Phenprocoumon) or more than one dosage of a substance on the index date
- For sensitivity analysis : Patient with any of the events defined in the combined endpoints [4 quarters prior to index date or “condition after”
- Patients with dialysis [4 quarters prior to index date]

Trial summary

Enrollment Goal

99999

Trial Dates

October 2016 - December 2016

Phase

N/A

Could I Receive a placebo

Products

Xarelto (Rivaroxaban, BAY59-7939)

Accepts Healthy Volunteer

Where to participate

Status	Institution	Location
Completed		Many Locations, Germany

Primary Outcome

Risk of ischemic stroke estimated as the number of hospitalizations with the ICD-10-GM diagnosis
Time Frame:
Within time of drug exposure (Retrospective period of 5 years and 3 months)
Safety Issue:
No
Risk of intracranial hemorrhage (ICH) estimated as the number of hospitalizations with the ICD-10-GM diagnosis
Time Frame:
Within time of drug exposure (Retrospective period of 5 years and 3 months)
Safety Issue:
No

Secondary Outcome

Risk of ischemic stroke or ICH estimated as the number of hospitalizations with the respective ICD-10-GM diagnosis
Time Frame:
Within time of drug exposure (Retrospective period of 5 years and 3 months)
Safety Issue:
No
Risk of systemic embolism (SE) estimated as the number of hospitalizations with the ICD-10-GM diagnosis
Time Frame:
Within time of drug exposure (Retrospective period of 5 years and 3 months)
Safety Issue:
No
Risk of transient ischemic attack (TIA) estimated as the number of hospitalizations with the ICD-10-GM diagnosis
Time Frame:
Within time of drug exposure (Retrospective period of 5 years and 3 months)
Safety Issue:
No
Risk of ischemic stroke or SE or TIA estimated as the number of hospitalizations with the respective ICD-10-GM diagnosis
Time Frame:
Within time of drug exposure (Retrospective period of 5 years and 3 months)
Safety Issue:
No

Trial design

Real-world comparative effectiveness of stroke prevention in patients with atrial fibrillation treated with rivaroxaban vs. vitamin k antagonists

Trial Type

Observational

Intervention Type

Drug

Trial Purpose

N/A

Allocation

N/A

Blinding

N/A

Assignment

N/A

Trial Arms

N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to Bayer products.